se of Newer Nueromuscular reversal agent - Sugammadex vs the conventional drug Neostigmine to enhance recovery after Cardiac surgery.
Phase 3
- Conditions
- Health Condition 1: I080- Rheumatic disorders of both mitraland aortic valves
- Registration Number
- CTRI/2024/03/063566
- Lead Sponsor
- Institutional Research Society
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
American Society of Anaesthesiologist (ASA) physical status
II - III undergoing elective open heart surgeries under general anaesthesia, and requiring
rocuronium-induced neuromuscular blockade will be included in the study. This includes patients undergoing -
1. Aortic valve replacement
2. Mitral valve replacement
3. Atrial septal defect closure
4. Ventricular septal defect closure
Exclusion Criteria
Aortic cross clamp time more than 100 minutes
Difficulty in weaning from cardiopulmonary bypass despite adequate inotropic support
Patients with preexisting DM, thyroid disorders and neuromuscular disorders
Postoperative hemodynamic instability making patient not suitable for weaning from ventilator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to extubation in post anesthesia care unit, which is the time in minutes from procedure <br/ ><br>stop to the time of extubationTimepoint: Upto 6 hours after surgery
- Secondary Outcome Measures
Name Time Method Respiratory parameters after surgery <br/ ><br>Delirium in the postoperative care unit <br/ ><br>Time to return of bowel sounds after surgery <br/ ><br>Time to first ambulation <br/ ><br>Time to discharge from ICUTimepoint: Upto 12 hours after surgery